Thoracic research and practice最新文献

{"title":"Global Burden of Tracheal, Bronchus, and Lung Cancer in Adults Over 55 Years Old Based on Socio demographic Status and Geographical and Gender Differences from 2010-2021.","authors":"Afrooz Mazidimoradi, Elham Shabani, Fatemeh Rezaei, Fariba Shahraki-Sanavi, Zahra Shahabinia, Leila Allahqoli, Hamid Salehiniya","doi":"10.4274/ThoracResPract.2024.24081","DOIUrl":"10.4274/ThoracResPract.2024.24081","url":null,"abstract":"<p><strong>Objective: </strong>This study presented the tracheal, bronchus, and lung cancer (TBLC) trend in adults ≥55 based on the socio-demographic index and geographical regions.</p><p><strong>Material and methods: </strong>We obtained annual TBLC data from 2010 to 2021 from the 2021 Global Burden of Disease (GBD) Study and analyzed the incidence, death rates, and disability-adjusted life years (DALYs) rates across different geographical classifications of 204 national and territorial.</p><p><strong>Results: </strong>In adults ≥55 years, the TBLC incidence rate decreased from 2010 to 2021 by globally 20.9% and 9.6% in males, while increasing by 3.8% in females. Approximately 60% of TBLC cases occurred in Asian countries. European countries exhibit the highest incidence rate (169.16 per 100,000). Males across all continents showed a decreasing trend, only the Americas reported a decreasing trend for women, with a noted change of 17.3%. The Western Pacific Region (World Health Organization region), East Asia (GBD region), Monaco, and countries with advanced health systems reported the highest incidence, death, and DALY numbers and rates for all genders. World Bank Upper middle-income countries recorded the highest DALY numbers and rates, incidence, and death numbers, all showing a downward trend, similar to high-income countries.</p><p><strong>Conclusion: </strong>The global burden of TBLC is predominantly in Asian countries (mainly East Asia), with a slower decrease in incidence, death, DALY, and burden rates. Therefore, reducing exposure to risk factors, expanding screening and diagnostic programs, especially for high-risk male smokers and females, and improving treatment procedures to reduce the progression of this cancer are urgent.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"155-175"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transbronchial Mediastinal Cryobiopsy Diagnostic Yield and Perioperative Patient Management: A Single Tertiary Center Experience.","authors":"Nadia Corcione, Alfonso Pecoraro, Andrea Fidecicchi, Severo Campione, Lina Zuccatosta, Giuseppe Failla","doi":"10.4274/ThoracResPract.2025.2024-12-4","DOIUrl":"10.4274/ThoracResPract.2025.2024-12-4","url":null,"abstract":"<p><strong>Objective: </strong>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is widely used to diagnose mediastinal lesions; however, small cytology samples from EBUS-TBNA may be inadequate in cases of benign lung diseases, hematologic disorders, and to assess the molecular profile of primary lung cancer (PLC). EBUS-guided transbronchial mediastinal cryobiopsy (TMC) obtains histological samples and potentially implies a higher diagnostic yield (DY) than EBUS-TBNA. The clinical impact of this technique and the perioperative patient management are still unclear. Our aim was to critically analyze our experience with TMC.</p><p><strong>Material and methods: </strong>A single center retrospective study was conducted to evaluate TMC DY and perioperative routine over 11 months (February 2023-January 2024).</p><p><strong>Results: </strong>Forty-one patients were included. The overall DY was 41.5% and 95.1% for EBUS-TBNA and TMC, respectively. TMC provided a higher DY than EBUS-TBNA in cases of hematologic disorders, benign diseases, and uncommon tumors (31% for EBUS-TBNA and 100% for TMC; 95% confidence interval (CI): 52.1-85.8, <i>P</i> < 0.001). For PLC, the DY and the assessment of immunohistochemical marker expression did not significantly differ between the two techniques (80% for EBUS-TBNA and 100% for TMC; 95% CI: -4.79-44.8, <i>P</i> = 0.13). The management of antithrombotic therapy was the same as that of EBUS-TBNA. Sedatives were administered to achieve deep sedation. After the procedure, no step-up in the level of care was observed, either in outpatients or in patients with a Charlson Comorbidity Index ≥5.</p><p><strong>Conclusion: </strong>TMC had a better DY than EBUS-TBNA in hematologic disorders, benign lung disease, and uncommon tumors, with an optimal tolerability profile.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"183-190"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243428/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considering Patient Perspective Through Visual Representatives: Telemedicine Gives Voice to Rare Interstitial Lung Disease Patients.","authors":"Nazlı Çetin, Sabri Serhan Olcay, Utku Tapan, Pelin Duru Çetinkaya, Francis X McCormack, Göksel Altınışık","doi":"10.4274/ThoracResPract.2025.2025-1-4","DOIUrl":"10.4274/ThoracResPract.2025.2025-1-4","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"208-210"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Pulmonary Genetic Variations in the Pathogenesis of Pediatric Postinfectious Bronchiolitis Obliterans.","authors":"Sedef Narin Tongal, Gülsüm Kayhan, Özge Yılmaz, Merve Öçalan, Hasan Yüksel","doi":"10.4274/ThoracResPract.2025.2024-11-1","DOIUrl":"10.4274/ThoracResPract.2025.2024-11-1","url":null,"abstract":"<p><strong>Objective: </strong>Postinfectious bronchiolitis obliterans (PIBO) is a chronic airway disease. The severity of the damage and the subsequent obstructive and inflammatory processes varies from one individual to another. The objective was to identify genetic variations that may be associated with pulmonary diseases in patients with PIBO.</p><p><strong>Material and methods: </strong>This retrospective descriptive study was carried out to define potential genetic changes that may be associated with PIBO. Medical records were used to obtain sociodemographic characteristics. Neutrophil, lymphocyte, platelet counts, immunoglobulins and C-reactive protein values, thoracic computed tomography (CT) findings and genetic analysis results for pulmonary panel using next-generation sequencing technology were recorded.</p><p><strong>Results: </strong>Sixteen patients were enrolled. Median age at diagnosis was 27.5 months (range: 7-195 months). Wheezing was the most common presenting symptom. The most prevalent finding on thoracic CT was a mosaic pattern. In all but one, a wide range of variations genes related to both pulmonary structure and function were identified. The genes identified included those related to primary ciliary dyskinesia (DNAH genes), surfactant metabolism disorder (ABCA3, CSF2RB), pulmonary fibrosis (MUC5B, SFTP), and bronchiectasis (SCNN1B).</p><p><strong>Conclusion: </strong>Heterozygous variations associated with pulmonary diseases, including the <i>MUC5B</i> and <i>DNAH</i> genes, and CSF2RB, were identified in most patients diagnosed with PIBO, which may have clinical significance. These data are valuable in hypothesis formation that may lead to the evaluation of these three genes in the pathogenesis of PIBO in children.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"191-196"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to: Long-term Effects of COVID-19 on Sleep Patterns.","authors":"Salma Batool-Anwar, Olabimpe S Fashanu, Stuart F Quan","doi":"10.4274/ThoracResPract.2025.2025-1-15","DOIUrl":"10.4274/ThoracResPract.2025.2025-1-15","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"211-212"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Long-term Effects of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Real-life Study with Five-year Follow-up.","authors":"Ayça Yanalak, Onur Yazıcı","doi":"10.4274/ThoracResPract.2025.2025-3-5","DOIUrl":"https://doi.org/10.4274/ThoracResPract.2025.2025-3-5","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the clinical, radiological, and functional outcomes of idiopathic pulmonary fibrosis (IPF) patients treated with nintedanib or pirfenidone, focusing on long-term efficacy, safety, and survival.</p><p><strong>Material and methods: </strong>A retrospective cross-sectional real-life study was conducted at a tertiary healthcare center between 2016 and 2021, including 93 IPF patients treated with either nintedanib (n = 41) or pirfenidone (n = 52). Data on demographics, pulmonary function tests [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and diffusing capacity for carbon monoxide], radiological assessments, exacerbations, mortality, and side effects were analyzed using appropriate statistical methods.</p><p><strong>Results: </strong>Both groups were comparable in age (nintedanib: 68.6 years; pirfenidone: 71.3 years) and gender distribution. Patients on pirfenidone had a higher body mass index (27.7 vs. 26.0 kg/m², <i>P</i> = 0.049) and more radiological involvement (<i>P</i> = 0.034). Baseline: Gender, Age, Physiology scores were lower in the nintedanib group (3.39 vs. 4.21, <i>P</i> = 0.007). Lung function (FVC, FEV1) was significantly better in the nintedanib group at two years; though differences were not sustained over five years. Side effects were more frequent with nintedanib (73.2% vs. 46.2%, <i>P</i> = 0.009), particularly affecting the gastrointestinal system. At five years after follow-up, mortality was higher in the pirfenidone group (53.4% vs. 17.5%, <i>P</i> = 0.02), although time from diagnosis to death was longer (33.8 vs. 19.0 months, <i>P</i> = 0.020).</p><p><strong>Conclusion: </strong>Pirfenidone may prolong survival in patients with severe disease and greater radiological involvement, while nintedanib showed lower mortality in milder disease. Treatment outcomes appear influenced by baseline characteristics, highlighting the need for individualized therapeutic strategies. Comprehensive studies involving more homogeneous patient groups are needed to clarify the comparative efficacy of these treatments.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144509919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Premature Deaths and Socio-economic Status: The Role of Fine Particulate Matter in Türkiye (2019).","authors":"Nilüfer Aykaç, Selin Çakmakcı Karakaya, Merve Erçelik Koncak, Orbay Tutku Seren, Sabri Serhan Olcay, Nil Kader Çağaç, Feride Marım, Susamber Dik, Şule Kızıltaş Bilgin, Maide Gözde İnam, İlknur Kaya, Khurshud Çağla Hüseynova, Remziye Can, Şeyma Tunç, Damla Karadeniz, Kübra Akyüz, Şaban Melih Şimşek, Neslihan Köse Kabil, Şerif Kurtuluş, Sebahat Genç, Yeşim Yasin, Ahmet Uğur Demir, Alpaslan Türkkan, Celaleddin Haluk Çalışır, Kayıhan Pala","doi":"10.4274/ThoracResPract.2025.2024-2-4","DOIUrl":"10.4274/ThoracResPract.2025.2024-2-4","url":null,"abstract":"<p><strong>Objective: </strong>Air pollution, particularly particulate matter (PM), is a leading environmental risk factor contributing to global morbidity and premature mortality. The World Health Organization's (WHO) AirQ+© software is a vital tool for assessing the health impacts of air pollution. Our study used this software to estimate premature deaths attributable to long-term particulate matter (PM_2.5) exposure in Türkiye in 2019 and explored its relationship with each province's socio-economic status.</p><p><strong>Material and methods: </strong>We conducted an ecological study using annual average PM_2.5 levels from air quality stations. Due to limited PM_2.5 measurements (only 16% of stations), we derived PM_2.5 values from PM₁₀ data using WHO's conversion coefficient for Türkiye.</p><p><strong>Results: </strong>We identified the provinces with the highest PM_2.5 concentrations and associated mortality: Iğdır, Şırnak, Çorum, Düzce, and Kahramanmaraş had the highest concentrations, while Erzurum, Çorum, Iğdır, Sinop, and Kütahya had the highest mortality rates per 100,000 population. No significant correlation was found between premature deaths and the socio-economic development index of each province. Our study estimated 37,768 premature deaths attributed to long-term PM_2.5 exposure in adequately monitored provinces.</p><p><strong>Conclusion: </strong>In 2019, Türkiye faced persistent air pollution, with PM_2.5 levels exceeding WHO's 2021 limits across all provinces and stations. Türkiye lacks specific PM_2.5 limits legislation. Our findings provide a fresh insight into the literature, highlighting policy reform needs. However, data deficiencies hindered analysis in some provinces, affecting nearly 20% of the population aged 30 and above and 31% of the total surface area. Therefore, the actual burden of air pollution-related deaths may be higher than our estimates, underscoring the need to address these challenges urgently.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"197-207"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latent Tuberculosis Infection in Inflammatory Rheumatic Diseases Before Biological and Synthetic DMARD Treatment: Results from Three Rheumatology Centers in Different Regions of Türkiye.","authors":"Abdulvahap Kahveci, Cansu Akleylek, Sevilay Batıbay","doi":"10.4274/ThoracResPract.2024.24098","DOIUrl":"10.4274/ThoracResPract.2024.24098","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to investigate the prevalence of latent tuberculosis (TB) infection (LTBI) and its associated factors in patients with inflammatory rheumatic diseases (IRDs) prior to the administration of biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs/tsDMARDs).</p><p><strong>Material and methods: </strong>A total of 402 patients with IRDs who were receiving bDMARDs/tsDMARDs from tertiary rheumatology centers in three different geographical regions were included in the study. Demographic, clinical, and TB-related characteristics were documented. The patients were divided into two groups, namely those with LTBI and non-LTBI, and their data were subjected to comparative analysis. The impact of various factors on LTBI was evaluated by regression analysis.</p><p><strong>Results: </strong>The prevalence of LTBI was 50.7% (204/402) before bDMARD/tsDMARD therapy. The proportion of male patients [108 (52.9%) vs. 84 (42.3%); <i>P</i> = 0.03] and the prevalence of smoking [102 (50.0%) vs. 64 (32.3%); <i>P</i> = 0.001] were statistically higher in the LTBI group. The preference for adalimumab was statistically lower in patients with LTBI (30.4%, 62/204 vs. 45.9%, 91/198; <i>P</i> = 0.021). Smoking [odds ratio (OR) 95% confidence interval (CI): 1.46 (1.16-1.65); <i>P</i> = 0.007], and duration of bDMARD use [OR 95% CI: 1.10 (1.03-1.17); <i>P</i> = 0.013] were significantly associated with LTBI. Isoniazid was used as the prophylactic agent in 96.45% (190/204) of patients, whereas there were no cases of TB reactivation among the three cohorts.</p><p><strong>Conclusion: </strong>The present study demonstrated that more than half of patients with IRDs undergoing advanced therapies have LTBI, with this infection being associated with male sex, smoking status, and duration of bDMARD use. Furthermore, this study indicates that appropriate screening and treatment of LTBI in patients with rheumatic diseases are associated with favorable clinical outcomes.</p>","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"176-182"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Global Epidemic of Silicosis Due to Artificial Stone: is Türkiye Next?","authors":"Metin Akgün, Özlem Kar Kurt","doi":"10.4274/ThoracResPract.2025.2025-4-2","DOIUrl":"10.4274/ThoracResPract.2025.2025-4-2","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"215-216"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on: Long-term Effects of COVID-19 on Sleep Patterns.","authors":"Mahmood Dhahir Al-Mendalawi","doi":"10.4274/ThoracResPract.2025.2025-1-7","DOIUrl":"10.4274/ThoracResPract.2025.2025-1-7","url":null,"abstract":"","PeriodicalId":75221,"journal":{"name":"Thoracic research and practice","volume":" ","pages":"213-214"},"PeriodicalIF":0.0,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144210450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}